Product Information
GVOKE HYPOPEN 1-PK 1 MG/0.2 ML is a brand product labeled by Xeris Pharmaceuticals, Inc., priced at $1603.4599 per ML under NDC 72065012111. Its NADAC has been published 223 times since May 18, 2022.
FDA first approved this application on Sep 10, 2019.
Strength
1 mg/.2mL
Manufacturer
Xeris Pharmaceuticals, Inc.NDC
72065012111
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
8/19/2026
Active Ingredients
GLUCAGONApproval Type
New Drug (NDA)
FDA Application
NDA212097FDA Approved
9/10/2019
On Market Since
9/10/2019
Pharmacological Classes
Price Statistics
The NADAC for GVOKE HYPOPEN 1-PK 1 MG/0.2 ML has been published 223 times since May 18, 2022, and over the history we have for it it has risen 12.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1603.4599 per ML |
|---|---|
| All-time high | $1603.4599 (Aug 19, 2026) |
| All-time low | $1427.3900 (May 18, 2022) |
| 52-week high | $1603.4599 |
| 52-week low | $1553.7960 |
| Median price | $1515.4017 |
| Average price | $1511.3441 |
| Largest weekly change | +3.0% (Feb 15, 2023) |
| Weeks tracked | 223 |
| Tracking since | May 18, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of GVOKE HYPOPEN 1-PK 1 MG/0.2 ML?
The current National Average Drug Acquisition Cost (NADAC) for GVOKE HYPOPEN 1-PK 1 MG/0.2 ML, manufactured by Xeris Pharmaceuticals, Inc., is $1603.4599 per ML (NDC 72065012111), effective Aug 19, 2026.
How has the price of GVOKE HYPOPEN 1-PK 1 MG/0.2 ML changed over time?
Over the history we have for it, the NADAC for GVOKE HYPOPEN 1-PK 1 MG/0.2 ML has risen 12.3%. It has been tracked across 223 weekly CMS publications since May 18, 2022.
What are the highest and lowest recorded NADAC prices for GVOKE HYPOPEN 1-PK 1 MG/0.2 ML?
Since May 18, 2022, the NADAC for GVOKE HYPOPEN 1-PK 1 MG/0.2 ML has ranged from a low of $1427.3900 (May 18, 2022) to a high of $1603.4599 (Aug 19, 2026), with a median of $1515.4017 per ML.
Are there cheaper alternatives to GVOKE HYPOPEN 1-PK 1 MG/0.2 ML?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GVOKE PFS 1-PK 1 MG/0.2 ML SYR, is $1600.2289 per ML — about 0% below GVOKE HYPOPEN 1-PK 1 MG/0.2 ML.
Who manufactures GVOKE HYPOPEN 1-PK 1 MG/0.2 ML?
GVOKE HYPOPEN 1-PK 1 MG/0.2 ML (NDC 72065012111) is labeled by Xeris Pharmaceuticals, Inc., and CMS classifies it as a brand product.